Published in CA Cancer J Clin on April 26, 2011
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest (2013) 1.17
TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle (2013) 1.12
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med (2013) 0.95
Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release (2011) 0.93
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One (2012) 0.92
Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway. Int J Oncol (2014) 0.90
Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia (2012) 0.89
High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol (2014) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.88
Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother (2015) 0.86
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther (2013) 0.86
The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer. PLoS One (2014) 0.85
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. Gynecol Oncol (2011) 0.84
Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health (2013) 0.84
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. JAMA Oncol (2015) 0.83
Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med (2015) 0.82
GOLPH3L is a Novel Prognostic Biomarker for Epithelial Ovarian Cancer. J Cancer (2015) 0.82
Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration. PLoS One (2015) 0.82
Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Eur J Nucl Med Mol Imaging (2015) 0.82
Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro. J Ovarian Res (2014) 0.82
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer (2016) 0.81
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Cancer Biol Ther (2013) 0.81
FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget (2016) 0.81
Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis. Int J Clin Exp Pathol (2015) 0.80
Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget (2014) 0.80
A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One (2015) 0.80
Highly-accurate metabolomic detection of early-stage ovarian cancer. Sci Rep (2015) 0.80
Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics (2014) 0.80
Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3 in vitro. Exp Ther Med (2015) 0.79
Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.79
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett (2015) 0.79
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. PLoS One (2013) 0.79
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol (2014) 0.79
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
Heterotypic three-dimensional in vitro modeling of stromal-epithelial interactions during ovarian cancer initiation and progression. J Vis Exp (2012) 0.78
Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials (2014) 0.78
Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer. Obstet Gynecol Sci (2014) 0.78
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis (2017) 0.78
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. Clin Cancer Res (2016) 0.77
MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget (2016) 0.77
Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. Int J Nanomedicine (2015) 0.77
MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner. Am J Transl Res (2016) 0.77
Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol (2016) 0.77
Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. Mol Med Rep (2015) 0.77
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo. Oncol Lett (2012) 0.77
Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models. BMC Cancer (2015) 0.77
The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol (2016) 0.77
Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis. Thorac Cancer (2015) 0.77
Stromal-epithelial crosstalk provides a suitable microenvironment for the progression of ovarian cancer cells in vitro. Cancer Invest (2013) 0.77
Stress induced premature senescence: a new culprit in ovarian tumorigenesis? Indian J Med Res (2014) 0.77
RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells. Mol Med Rep (2015) 0.76
Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study. Clin Med Insights Oncol (2016) 0.76
Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med (2016) 0.76
Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. EJNMMI Res (2014) 0.76
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog (2014) 0.76
Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo. Onco Targets Ther (2016) 0.76
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm Res (2015) 0.76
Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24. J Cancer (2017) 0.75
MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer. Sci Rep (2016) 0.75
Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. J Ovarian Res (2016) 0.75
Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. Oncol Lett (2016) 0.75
The sL1CAM in sera of patients with endometrial and ovarian cancers. Arch Gynecol Obstet (2016) 0.75
Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer. Int J Gynecol Cancer (2016) 0.75
Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer. Oncotarget (2016) 0.75
Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis. Onco Targets Ther (2016) 0.75
Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. Sci Rep (2016) 0.75
The Role of Completion Surgery in Ovarian Cancer. J Obstet Gynaecol India (2015) 0.75
Research Progress of MicroRNA in Early Detection of Ovarian Cancer. Chin Med J (Engl) (2015) 0.75
Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. Int J Mol Sci (2017) 0.75
Retinoic acid aliphatic amide inhibits the AMPK-HIF-1α pathway in human ovarian cancer. Int J Clin Exp Pathol (2015) 0.75
TLR-exosomes exhibit distinct kinetics and effector function. Sci Rep (2017) 0.75
Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environ Res (2017) 0.75
Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget (2017) 0.75
Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases. Cell Death Dis (2016) 0.75
Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. Br J Radiol (2015) 0.75
Preparation of magnetic mesoporous silica nanoparticles as a multifunctional platform for potential drug delivery and hyperthermia. Sci Technol Adv Mater (2016) 0.75
Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer. PLoS One (2017) 0.75
Complications from Surgeries Related to Ovarian Cancer Screening. Diagnostics (Basel) (2017) 0.75
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene (2016) 0.75
Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma. J Biomed Res (2012) 0.75
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Ther (2016) 0.75
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis. PLoS One (2016) 0.75
Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer (2017) 0.75
A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. Oncotarget (2016) 0.75
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med (2016) 0.75
Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. Sci Rep (2016) 0.75
BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls. Medicine (Baltimore) (2015) 0.75
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. J Ovarian Res (2017) 0.75
Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). Cancer Chemother Pharmacol (2016) 0.75
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. Br J Cancer (2016) 0.75
Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition. PLoS One (2015) 0.75
Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin Transl Oncol (2017) 0.75
Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. Exp Ther Med (2017) 0.75
Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells. Exp Ther Med (2017) 0.75
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol (2017) 0.75
Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci Rep (2017) 0.75
An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. Oncotarget (2017) 0.75
Ovarian Cancer Incidence Corrected for Oophorectomy. Diagnostics (Basel) (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Cancer of the ovary. N Engl J Med (2004) 11.21
Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell (2002) 9.61
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet (2009) 6.65
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 5.81
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA (1993) 5.31
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (1993) 3.86
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol (2004) 3.49
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol (2008) 3.46
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Ovarian carcinoma diagnosis. Cancer (2000) 3.12
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med (1990) 2.97
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol (2000) 2.68
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2004) 2.66
Hormone therapy and ovarian cancer. JAMA (2009) 2.65
Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol (2010) 2.65
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol (1996) 2.21
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2005) 1.91
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol (1999) 1.87
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer (2005) 1.83
Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol (2000) 1.83
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol (2007) 1.70
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol (1998) 1.68
Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer (2008) 1.66
Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol (2004) 1.66
Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol (2007) 1.63
Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol (2005) 1.62
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol (1994) 1.60
Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) (1998) 1.55
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol (2004) 1.50
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res (2007) 1.49
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.45
Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer (2004) 1.45
Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol (1992) 1.44
Carboplatin desensitization. Ann Allergy Asthma Immunol (2004) 1.42
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer (2010) 1.40
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer (2000) 1.37
Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer (2001) 1.37
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol (2010) 1.37
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2003) 1.33
Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer (1989) 1.33
Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol (1998) 1.33
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.28
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol (2002) 1.24
Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev (2008) 1.22
Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol (2006) 1.18
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.14
Hereditary ovarian cancer. Crit Rev Oncol Hematol (2008) 1.14
Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist (2006) 1.11
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer (2009) 1.08
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol (2009) 1.07
Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol (2010) 1.06
Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol (1994) 1.06
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol (2006) 1.03
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (1998) 1.02
Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol (2003) 1.02
Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol (2007) 1.02
Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol (2003) 1.01
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol (2005) 0.99
Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol (2005) 0.95
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Is the easier way ever the better way? J Clin Oncol (2011) 2.41
Recurrent micropapillary serous ovarian carcinoma. Cancer (2002) 2.24
Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology (2007) 2.18
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 1.92
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol (2005) 1.81
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 1.47
Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol (2009) 1.28
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer (2007) 1.22
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer (2009) 1.18
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol (2011) 1.15
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.14
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.08
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer (2009) 1.08
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 1.04
A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res (2003) 1.02
A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage (2010) 1.01
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer (2009) 1.01
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol (2007) 1.00
Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol (2007) 0.98
Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer (2007) 0.98
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2008) 0.98
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2006) 0.97
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat (2011) 0.97
Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol (2005) 0.95
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat (2013) 0.92
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol (2011) 0.91
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) (2011) 0.90
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol (2009) 0.90
Breast cancer risk reduction. J Natl Compr Canc Netw (2010) 0.88
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol (2009) 0.88
Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol (2006) 0.87
Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol (2013) 0.87
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat (2011) 0.87
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol (2013) 0.87
Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol (2002) 0.86
Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol (2005) 0.85
Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol (2005) 0.85
Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des (2012) 0.84
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol (2009) 0.84
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol (2004) 0.84
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.83
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 0.83
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat (2013) 0.81
Analysis of contemporary trends in access to high-volume ovarian cancer surgical care. Ann Surg Oncol (2009) 0.81
Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation. Gynecol Oncol (2006) 0.81
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer (2010) 0.80
Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. J Ovarian Res (2010) 0.79
Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin Oncol (2006) 0.78
Breast cancer risk reduction. J Natl Compr Canc Netw (2007) 0.78
Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.78
Ovarian cancer clinical practice guidelines. J Natl Compr Canc Netw (2004) 0.77
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs (2012) 0.77
Planning treatment for women with recurrent epithelial ovarian cancer. Oncology (Williston Park) (2013) 0.75
The "luxury" of second malignancies. Gynecol Oncol (2011) 0.75
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. Breast Cancer Res Treat (2002) 0.75